The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity. - Archive ouverte HAL Access content directly
Journal Articles Cancer Immunology, Immunotherapy Year : 2016

The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.

(1) , (2) , (3) , (4) , (2) , (1) , (3) , (5) , (3) , (6) , (1) , (1)
1
2
3
4
5
6

Abstract

Malignant transformations are often associated with aberrant glycosylation processes that lead to the expression of new carbohydrate antigens at the surface of tumor cells. Of these carbohydrate antigens, the Tn antigen is particularly highly expressed in many carcinomas, especially in breast carcinoma. We designed MAG-Tn3, a fully synthetic vaccine based on three consecutive Tn moieties that are O-linked to a CD4+ T cell epitope, to induce anti-Tn antibody responses that could be helpful for therapeutic vaccination against cancer. To ensure broad coverage within the human population, the tetanus toxoid-derived peptide TT830-844 was selected as a T-helper epitope because it can bind to various HLA-DRB molecules. We showed that the MAG-Tn3 vaccine, which was formulated with the GSK proprietary immunostimulant AS15 and designed for human cancer therapy, is able to induce an anti-Tn antibody response in mice of various H-2 haplotypes, and this response correlates with the ability to induce a specific T cell response against the TT830-844 peptide. The universality of the TT830-844 peptide was extended to new H-2 and HLA-DRB molecules that were capable of binding this T cell epitope. Finally, the MAG-Tn3 vaccine was able to induce anti-Tn antibody responses in cynomolgus monkeys, which targeted Tn-expressing tumor cells and mediated tumor cell death both in vitro and in vivo. Thus, MAG-Tn3 is a highly promising anticancer vaccine that is currently under evaluation in a phase I clinical trial.
Fichier principal
Vignette du fichier
art%3A10.1007%2Fs00262-016-1802-0.pdf (1.77 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

pasteur-01291786 , version 1 (22-03-2016)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Daphné Laubreton, Sylvie Bay, Christine Sedlik, Cécile Artaud, Christelle Ganneau, et al.. The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.. Cancer Immunology, Immunotherapy, 2016, 65 (3), pp.315-25. ⟨10.1007/s00262-016-1802-0⟩. ⟨pasteur-01291786⟩
441 View
275 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More